India, Oct. 20 -- Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis (UC) and Crohn's disease (CD) through Week 44 of the RELIEVE UCCD long-term extension study.
Duvakitug is an investigational monoclonal antibody targeting TL1A, a protein involved in inflammation and potentially fibrosis in inflammatory bowel disease (IBD).
In patients with UC, clinical remission rates at Week 44 were 47% with the 450 mg dose and 58% with the 900 mg dose, administered subcutaneously every four weeks. Clinical response rates were 82% and 87%, respectively, while endoscopic improvement rates reached 59% and 63%.
In patien...